Short-Term Clinical Experience with a Dedicated Venous Nitinol Stent: Initial Results with the Sinus-Venous Stent  by de Wolf, M.A.F. et al.
Eur J Vasc Endovasc Surg (2015) 50, 518e526Short-Term Clinical Experience with a Dedicated Venous Nitinol Stent:
Initial Results with the Sinus-Venous Stent
M.A.F. de Wolf a,*, R. de Graaf b, R.L.M. Kurstjens a, S. Penninx a, H. Jalaie c, C.H.A. Wittens a,c
a Department of Vascular Surgery and Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands
b Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands
c Department of Vascular Surgery, University Hospital RWTH Aachen, Aachen, Germany* Cor
HX Ma
E-ma
1078
Elsevie
http:WHAT THIS PAPER ADDS
Endovascular treatment in patients with deep venous occlusive or obstructive disease, by PTA and stent
placement, is an emerging ﬁeld; however, dedicated venous stents have only recently become available. This
study describes a ﬁrst experience with one such device, the sinus Venous stent. This device distinguishes itself
from previously used stent designs aimed at the arterial system by increased radial force and ﬂexibility, and
greater diameter and length. It is postulated that dedicated venous stents will become the new standard for
treatment of venous compression and post-thrombotic syndromes in the future.Objective: Deep venous stenting has become the primary treatment option for chronic venous obstructive
disease, both for iliac vein compression and post-thrombotic venous lesions. Until recently, only stents aimed at
arterial pathology were used, because no dedicated venous stents were available. However, three such stents
have now become available. These venous stents are characterized by increased length, diameter, ﬂexibility, and
radial force. This study reports an early experience with one of these devices; the sinus Venous stent (OptiMed
GmbH, Ettlingen, Germany).
Methods: Between March 2012 and July 2014, 75 patients were treated with the sinus Venous stent: 35 cases of
iliac vein compression syndrome and 40 cases of unilateral chronic obstruction in post-thrombotic syndrome
(PTS). Diagnosis of relevant obstruction was made using clinical evaluation, duplex ultrasound, and magnetic
resonance venography. Patency during follow up was assessed with duplex ultrasound. Clinical improvement was
assessed by VCSS, Villalta score, rate of ulcer healing, and improvement of venous claudication.
Results: The cumulative patency rates at 3, 6, and 12 months were 99%, 96%, and 92%, respectively. The
cumulative assisted primary patency rates were 99% at 3, 6, and 12 months. The cumulative secondary patency
rate at 12 months was 100%. Differences exist in patency rate between the subgroups of non-thrombotic and
post-thrombotic, with the ﬁrst showing no re-occlusions. All re-thromboses in the PTS group were treated by
ancillary treatment modalities. VCSS and Villalta score decreased signiﬁcantly after stenting, as did venous
claudication. Morbidity was low without clinically relevant pulmonary embolism, and mortality was nil. Although
two out of seven ulcers healed temporarily, no ulcer remained healed at 12 months follow up.
Conclusion: Short-term clinical results using the sinus Venous stent are excellent, with signiﬁcant symptom
reduction, low morbidity rates, and no mortality. Loss of stent patency is seen less often compared with arterial
stents described in the literature.
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Therapy for chronic deep venous disease has long been
characterized by the sole use of conservative treatment
modalities, both in cases of valvular insufﬁciency and
venous obstructive disease. Open surgical or endovascular
approaches were reserved for the most severe cases, which
still holds true for deep venous valvular insufﬁciency. In
recent years, however, the treatment options in chronic
Initial Sinus-Venous Results 519deep venous obstructive disease have changed dramatically.
Endovascular treatment, by use of percutaneous trans-
luminal angioplasty (PTA) and stenting of post-thrombotic
obstructions and venous compression syndromes, such as
May-Thurner syndrome (MTS), has become standard care in
a large number of specialized centers worldwide. The low
morbidity, absence of mortality, and excellent short and
long-term results mean that worldwide interest in this type
of treatment is rapidly increasing and more and more
centers are starting to offer this treatment. It is, therefore,
remarkable that until very recently no stents dedicated to
deep venous pathology were available.
Neglén et al. showed good results with the Wallstent, a
metal stent frequently used in arterial pathology, with high
radial force, although limited ﬂexibility and poor positioning
qualities.1 Also, nitinol stents have been used and show
comparable results between study groups.2 Recent study of
arterial designed self-expanding nitinol stents in a mostly
post-thrombotic population, showed patency rates of 74%,
81%, and 96% at 1 year for primary, assisted primary, and
secondary patency, respectively.3 The arterial design, how-
ever, incorporates properties that might hamper applica-
bility in the venous system.4 Arterial and venous anatomy
and hemodynamics differ greatly in physiological and
pathophysiological conditions; especially in terms of shear
stress, vessel diameter, and ﬂexibility. Moreover, PTA and
stenting in arterial disease is generally reserved for pa-
thology of athero-thrombotic origin, without scarring of the
vessel wall and or external compression.
Recently a number of dedicated venous stents have been
announced or became available; namely the Veniti Vici
(VENITI inc., St. Louis, MO, USA), Zilver Vena (Cook, Bloo-
mington, IN, USA), and sinus Venous (OptiMed, Ettlingen,
Germany). All three devices are designed to accommodate
the need for greater length, diameter, ﬂexibility, and radial
force in the venous system. To the authors’ knowledge, only
clinical data regarding the Zilver Vena have been published.
O’Sullivan et al. showed excellent results for the Zilver Vena
stent in a challenging population with many acute DVT
patients and malignant venous obstructions; they reported
a short-term patency rate of 85%.5
This study evaluates safety and short-term clinical
outcome when using the sinus Venous stent in routine
patient care at a tertiary venous center. As iliac vein
compression syndromes differ greatly in their etiology from
post-thrombotic disease, use of the device will be evaluated
separately for both types of pathology.METHODS
The study included 75 patients treated for symptoms and
complaints related to unilateral chronic iliofemoral venous
obstructive disease with the sinus Venous stent at a tertiary
referral hospital, between March 2012 and July 2014. Pa-
tients who were suspected of having iliofemoral deep
venous obstruction received both duplex ultrasonography
(DUS) imaging and magnetic resonance venography (MRV)
to conﬁrm the diagnosis.6 Patients were included when: (A)signs of unilateral iliofemoral deep venous obstruction
were present on DUS and MRV (>50% diameter stenosis
and the presence of a collateral network), (B) clinically
signiﬁcant signs and symptoms of chronic obstructive
venous disease were present, and (C) the femoral and deep
femoral veins were patent. Patients with inferior vena cava
involvement or bilateral iliofemoral occlusive disease were
excluded. Furthermore, patients were excluded in whom
post-thrombotic aberrations extended below the level of
the saphenofemoral junction in the common femoral vein,
as these patients are treated in a hybrid fashion, stent
placement combined with endophlebectomy and AV ﬁstula
creation.7 Moreover, patients with a history of DVT less
than 1 year ago were excluded as sufﬁcient natural
recanalization might still occur.8 Upon intake baseline data
were collected, consisting of CEAP, Venous Clinical Severity
Score (VCSS), Villalta score, and assessment of venous
claudication.9e11 Venous claudication was deﬁned as the
onset or worsening of pain and/or heaviness during (mild)
exercise, which subsides during rest, especially when sitting
or lying down. Venous claudication was only considered in
patients with a proven venous obstruction. The location
and extent of obstruction or external compression, the
presence of collateral veins, the inﬂow at the common
femoral vein from all three major branches (great saphe-
nous vein, femoral vein and deep femoral vein), the
outﬂow through the inferior vena cava and valve compe-
tence (< 0.5 seconds of reﬂux) all were evaluated. Left iliac
vein compression (LIVC) or right iliac vein compression
syndrome was considered when external compression of
the common iliac vein (CIV) created >50% diameter
reduction at this point as shown by DUS and/or MRV and
collaterals were present.12,13
Duplex ultrasonography
DUS examination was done using a Hitachi Aloka ProSound
ALPHA 7 Premier machine (Aloka, Tokyo, Japan) and con-
sisted of scanning the venous system from the supra-renal
vena cava down to the common femoral vein in the su-
pine position with a convex array transducer, UST-9130
(frequency range, 3e6 MHz). Using a high-frequency UST-
5411 (frequency range, 5e16 MHz) compound linear array
transducer with pulsed wave Doppler (5 MHz), scanning
from the upper groin to below the knee to test for distal
obstructive lesions (>50% diameter reduction) and valvular
incompetence (>0.5s reﬂux), in the standing position, was
performed.
Magnetic resonance venography
All MRV examinations were performed on a 1.5-T MRI
system (Achieva, Philips Medical Systems, Best, the
Netherlands). The technique has been described in detail
before.6 In short, a dedicated 12 element phased array
peripheral vascular coil with a cranio-caudal coverage of
128 cm (Philips Medical Systems) was used for signal
reception. A ﬁxed dose of 20 mL gadobutrol (Gadovist 1.0,
Bayer Schering Pharma, Berlin, Germany) was administered
520 M.A.F. de Wolf et al.intravenously as a single dose at a rate of 1.0 mL/s in the
median cubital vein, using a remote controlled injection
system (Medrad Spectris, Indianola, PA, USA). A ﬁve station
three dimensional ultrafast gradient echo (TFE) sequence
with fat suppression (SPIR) was used for high resolution
imaging of the venous vasculature from the popliteal veins
up to the right atrium.PTA and stenting
Procedures were performed in a dedicated angiosuite
(AlluraClarity, Philips Medical Systems, Eindhoven, the
Netherlands). All interventions in post-thrombotic syn-
drome (PTS) patients were performed under general anes-
thesia, while iliac vein compressions were treated under
local anesthesia. Heparin (5.000 IU) was administered to all
patients currently not using oral anticoagulants, and cou-
madin was continued in all other cases (a maximum INR of
4 was accepted at the time of intervention). Venous access
was obtained through the ipsilateral femoral vein, at least
15 cm distal to the femoral conﬂuence under ultrasound
guidance. A 10F sheath was needed to facilitate stent
introduction. The technique for traversing stenotic and
occluded venous segments has been described before.14
Pre-dilatation to the size of the anticipated stent is essen-
tial for sinus Venous stents. Pre-dilatation was done
increasing in size from 12 to 16 mm from the common
femoral vein to the common iliac vein (12 mm powerﬂex
and 16 mm maxi LD, Cordis, Johnson & Johnson, Diegem,
Belgium; 14 mm Armada, Abbott, North Chicago, IL, USA).
Maximum pressure needed for full balloon expansion was
12 atm. All venous segments were stented with the sinus
Venous. Post-dilatation was always performed. Post-
stenting assessment of in and outﬂow was done by single
plane antero-posterior angiography. Conebeam CT imaging
was performed to evaluate stent conﬁguration and appo-
sition. Post intervention, patients were generally discharged
the next day. The anticoagulation regimen consisted of 6
months of treatment with coumadin, with a target INR of
3e4, according to Dutch guidelines for thrombosis ser-
vice.15 This regimen was started the evening after the
intervention. Full dose tinzaparine was started directly post-
intervention and continued until the INR was >3 on two
separate days. Antiplatelets were not used. In patients
already using coumadin prior to the intervention, these
drugs were continued during hospitalization.Follow up
Standardized follow up was performed at 2 and 6 weeks
and 3, 6, and 12 months post intervention. Follow up data
collection consisted of VCSS and Villalta score assessment,
rate of relief of venous claudication and ulcer healing
(deﬁned as full re-epithelialization). DUS was performed to
assess patency at every visit. Patency was deﬁned as ﬂow in
a lumen with <50% diameter compared with the stent
diameter. All data were collected prospectively using a
preset protocol.Statistical analysis
Frequencies and percentages were used to present cate-
gorical data. Median values with the range were used for
continuous data. Categorical data were analyzed by the c2
test. KaplaneMeier survival analysis was used to calculate
patency rates. An a of .05 was used to indicate statistical
signiﬁcance.
Ethical approval for research
Under Dutch law, patients treated at a university hospital
give automatic consent for their anonymized data to be
used in research, unless explicit objections are made.
RESULTS
Demographics
Seventy-ﬁve patients with unilateral chronic ilio-femoral
venous obstruction (CVO) were treated by placement of
the sinus Venous stent during the study period. The median
age was 45 years (range 18e77), and 49 (65%) patients
were female. Complaints and symptoms were caused by
post-thrombotic disease in 40 (53%) patients. In the other
35 (47%) patients, CVO was caused by primary iliac vein
compression syndrome (left sided in 33 patients). In the
post-thrombotic patient group, 35 (88%) had suffered a DVT
in their medical history. In the other ﬁve patients no DVT
was ever diagnosed clinically; however, there were signs on
MRV and DUS of vein wall scariﬁcation and trabeculation in
the common and/or external iliac vein, consistent with prior
DVT (Table 1). All post-thrombotic ilio-femoral obstructive
lesions were occlusive on the intra-procedural venogram.
Post-thrombotic occlusion was restricted to the CIV in two
(5%) patients, present in CIV and external iliac vein (EIV) in
ﬁve (13%), present in the EIV and common femoral vein
(CFV) above the sapheno-femoral conﬂuence in four (10%)
and extending from the CIV to the CFV above the sapheno-
femoral conﬂuence in 29 (73%) patients. C class of CEAP
was C4e6 (i.e. skin changes) in 21 (28%) patients. Forty
(53%) patients presented with venous claudication. Based
on the Villalta scale, 13 (33%) legs were scored as having
mild, 11 (28%) moderate, and 13 (33%) severe PTS. In three
(8%) patients the Villalta scale was <5 points, that is venous
claudication was the indication for treatment in those pa-
tients (which highlights the inability of the Villalta scale to
adequately assess PTS in some cases). Venous claudication
was present in 25 (63%) patients in the PTS and 16 (46%) in
the iliac vein compression groups. Seven (9%) patients had
an active venous ulcer, four in the PTS, and three in the iliac
vein compression syndrome group. Other demographics
and subdivision into subgroups can be found in Table 1.
Procedure
All post-thrombotic occlusions required recanalization.
Technical success was achieved in all cases. In 43 patients
(57%) one stent was used, in 27 patients (36%) two stents,
and in ﬁve patients (7%) three stents were used. When
applicable, the stent was placed as accurately as possible at
Table 1. Demographics of the total, PTS, and iliac vein compression subgroups.
Baseline Total PTS Iliac vein compression
N 75 40 35
Number of females 49 (65%) 24 (53%) 25 (71%)
Average age (years) 45 (17e77) 45 (17e68) 44 (18e77)
Single DVT 38 (51%) 28 (70%) 5 (14%)
Recurrent DVT 9 (12%) 7 (18%) 2 (6%)
Silent DVTa 5 (7%) 5 (13%) 0 (0%)
Time between DVT and Treatment (years) 6 (1e37) 6 (1e37)
Left sided DVT 29 (83%)
Right sided DVT 5 (14%)
Bilateral DVT 1 (3%)
Left sided stenting 72 (96%) 39 (98%) 33 (94%)
Right sided stenting 8 (11%) 6 (15%) 2 (6%)
C-class 0 8 (11%) 4 (10%) 4 (11%)
C-class 1 9 (12%) 7 (18%) 2 (6%)
C-class 2 13 (17%) 6 (15%) 7 (20%)
C-class 3 24 (32%) 11 (28%) 13 (37%)
C-class 4 11 (15%) 6 (15%) 5 (14%)
C-class 5 3 (4%) 2 (5%) 1 (3%)
C-class 6 7 (9%) 4 (10%) 3 (9%)
Median Villalta 11.5 (2e24)
Venous claudication 40 (53%) 25 (63%) 16 (46%)
Superﬁcial venous reﬂux 61 (81%) 33 (83%) 28 (80%)
Deep venous reﬂux 19 (25%) 12 (30%) 7 (20%)
Perforator vein reﬂux 17 (23%) 5 (13%) 12 (34%)
a Silent DVT: no anamnestic history of DVT, but clear signs of previous DVT on imaging.
Initial Sinus-Venous Results 521the iliac conﬂuence to cover the obstruction, with special
care not to cover the contralateral inﬂow. In three patients,
however, one in the PTS group and two in the iliac vein
compression group, positioning was deemed too central
into the inferior vena cava (IVC), touching the IVC wall and
thereby covering the contralateral inﬂow. No further action
was taken. In a fourth patient acute thrombosis of the
stented tract was observed during the procedure and was
directly and successfully treated by percutaneous throm-
bectomy. Throughout follow up this patient’s stents
remained patent. Intra-procedural kinking and/or fracture
of stents were not seen.Figure 1. Ultrasound control after stenting the common iliac vein
on the left side to treat May-Thurner syndrome, showing the
typical oval shape of the stent with sufﬁcient radial force to lift the
overlying right common iliac artery. Smallest intraluminal diameter
is 7.6 mm, compared with 12 mm more distally, but with a very
adequate surface area of 1.23 cm2.Follow up
The ultrasound examination at 2 weeks showed suboptimal
positioning of the CIV stent in two patients with iliac vein
compression lesions. In both cases, the stents were placed
too peripherally, resulting in persistent compression of the
left CIV by the overlying right common iliac artery (which
did not require re-stenting as the recurrent stenosis was
<50%). Optimal stent distention was seen in all cases distal
to the CIV. Mild compression, that is oval rather than round
conﬁguration of the stent was noticed at the level of the
left common iliac vein because of the overriding right iliac
artery in most cases (Fig. 1); however, no signiﬁcant diam-
eter stenosis (>50%) was seen, compared with the diam-
eter of a fully expanded stent.
Patient follow up had a median duration of 5.4 (range
1.0e18.0) months. The overall cumulative primary patency
was 99% at 3 months, 96% at 6 months, and 92% at 12months. Assisted primary patency rates were 99% at 3, 6
and 12 months, and the secondary patency rate was 100%
during the total follow up period (Fig. 2A). Cumulative pri-
mary patency rates for the iliac vein compression group
were 100% during follow up (Fig. 2B). The cumulative pri-
mary patency rates of the post-thrombotic group at 3, 6,
and 12 months were 97%, 93%, and 85%, respectively
(Fig. 2C). For all reported patency rates the standard error
of the mean was <10.0. Loss of primary patency was seen
in three post-thrombotic patients, in all cases re-thrombosis
occurred (Fig. 3). Residual compression in one patient with
a history of a spondylodesis by metal rods and screws led to
Figure 2. KaplaneMeier analysis of patency rates of (A) the total
population, (B) the iliac vein compression syndrome population,
and (C) the PTS population.
522 M.A.F. de Wolf et al.quick stenosis and thrombosis of the stented common iliac
vein. This was treated by catheter directed thrombolysis
followed by re-stenting of the CIV with a high radial
strength balloon expendable stent (Andrastent XL 43 mm,
Andramed, Reutlingen, Germany). In a second patient the
stent placed in the CIV was mistakenly stretched duringplacement, leading to a signiﬁcant gap between the struts
of the stent; at this point the right common iliac artery
slipped into the gap causing a persistent stenosis during
follow up. This was treated by re-stenting with a second
well placed sinus Venous stent. In the third patient, with a
history of IV drug abuse into the common femoral vein, the
ﬁbrotic vein was not pre-dilated with enough pressure.
During follow up, signiﬁcant stenosis was seen at this level,
which was treated solely using high pressure re-PTA. Other
complications during follow up are noted in Table 2.Clinical improvement
Median Villalta score in the PTS group decreased from 11.5
(2e24) before treatment to 5.0 (0e16) at last follow up,
which constituted a decrease of 6.5 (p  .001). VCSS
decreased 3 points, from 8 (3e21) pre-intervention to 5
(0e16) at last follow up in the PTS group and decreased 2
points from 6 (2e19) to 4 (1e16) in the iliac vein
compression group, both decreases were statistically sig-
niﬁcant (p  .001 and p ¼ .019). Venous claudication
subsided in 18 out of 25 patients in the PTS group
(p  .0001) and in 14 out of 16 patients in the iliac vein
compression group (p ¼ .0002). Two of four ulcers healed in
the PTS group, and none healed in the iliac vein compres-
sion group. Both healed ulcers recurred during follow up.DISCUSSION
In this study, short-term results for use of the segmental
sinus Venous stent in chronic venous obstructive disease
are very favorable, both in the post-thrombotic syndrome
and iliac vein compression syndrome. In a previous study,
initial data on PTA and stenting in a similar population from
the same center were presented.3 In both studies, PTA and
stenting were shown to be safe and feasible when using
self-expandable nitinol stents with good patency rates, mild
complication rates, and no mortality. Other authors have
shown similar favorable results of deep venous stenting
during recent decades, including those series in which pa-
tients were stented with other stent types, especially the
Wallstent (Boston Scientiﬁc).1,16,17 As the Wallstent suffers
from signiﬁcant foreshortening, precise positioning is
sometimes difﬁcult in inexperienced hands and occurrence
of skip lesions may occur. Therefore, earlier reports
mentioned the need for considerable overlapping of mul-
tiple stents to prevent incomplete treatment of obstructive
lesions. Multiple centimeter overlaps make the stented
segment even more rigid. Furthermore, to prevent retro-
grade migration the Wallstent has to be placed well into the
inferior vena cava, potentially impairing contralateral
outﬂow and increasing the risk of contralateral iliac vein
thrombosis. Arterial designed nitinol stents have their own
shortcomings and differ from venous designed stents in
several ways.
Firstly, the diameter of a vein is greater than that of an
artery. This is particularly important in the common iliac
tract as generally stent diameters of 16e20 mm are
Figure 3. Loss of patency cases. (A) X-ray in lateral projection showing sub-optimal stent conﬁguration because of extensive spondylodesis
material leaving a remaining compression (white arrow). (B) Cone beam CT imaging showing signiﬁcant stent compression, non-responding
to repeated balloon angioplasty. (C) Completion angiography after stenting for post-thrombotic iliac vein obstruction showing a gap
between stent segments at the level of the overlying common iliac artery resulting from sub-optimal deployment technique. (D) Cone
beam CT imaging showing persistent compression caused by lack of stent material and therefore crush resistance at the level of the
common iliac artery (white arrow). (E) Adequate surface area after re-stenting.
Table 2. Complications after stent placement.
Complications Total population PTS Iliac vein compression
N 75 40 35
Proximal stent extension into vena cava 3 (4%) 1 (3%) 2 (6%)
Minor bleeding during admission 1 (1%) 1 (3%) 0 (0%)
Stent related pain needing re-admission 1 (1%) 1 (3%) 0 (0%)
Residual stent compression 2 (3%) 2 (5%) 0 (0%)
Stent tapering 2 (3%) 2 (5%) 0 (0%)
Stent stenosis 2 (3%) 2 (5%) 0 (0%)
Anticoagulation related minor bleeding during
follow-up
4 (5%) 4 (10%) 0 (0%)
Stent placed proximally of common iliac vein
compression location
3 (4%) 2 (5%) 1 (3%)
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diameters.
Secondly, post-thrombotic obstructions generally cover a
greater length of the vein compared with arterial obstruc-
tive lesions. Therefore, more than one stent is often
required in post-thrombotic patients when using arterial
nitinol stents. The increased overlapping areas of the stents
further reduce ﬂexibility. Thirdly, post-thrombotic veins are
often heavily scarred and have ﬁrm intraluminal ﬁbrotic
strands, which may extend over relatively long segments.
Pre-dilatation, sometimes with high pressure balloons, is
needed to break these ﬁbrotic strands and dilate the ﬁbrotic
vein wall. A stent with sufﬁcient resistive radial force is
needed to maintain this diameter. This force in arterial
designed stents is most often insufﬁcient. In iliac vein
compression syndromes the local pressure on a vein caught
between the overlying artery and bony structures is high,
and therefore calls for stents with sufﬁciently high resistive
radial force.
Fourthly, in contrast to arteries, normal veins have a less
supported wall and are more susceptible to external forces.
Post-thrombotic veins might be inﬂuenced less because
of the ﬁbrotic changes. Nevertheless, it is generallyFigure 4. Arterial stent design (sinus XL stent, OptiMed GmbH, Ettlinge
stent, OptiMed GmbH, Ettlingen, Germany). (A) Forcing an arterial desi
venous stents can be shaped easily into an “S” curve. (C) Oblique pr
kinking on the left (white arrow) and straightening of a stent-in-stent o
May-Thurner compression, adapting perfectly to the venous anatomy.recommended to land a stent in a healthy vein segment. It
is therefore conceivable that particular stent properties
have an effect on the integrity of the vein at this location.
Optimally, stents implanted within venous structures should
be able to move effortlessly with every movement of the
vein. Stents with excessive rigidity might dictate the shape
of the vein, thereby perhaps creating sub-optimal hemo-
dynamics or damage to the vein wall causing stenosis,
occlusion, or insufﬁcient ﬂow. This is especially the case
when stents cross the internal iliac vein and inguinal liga-
ment where sufﬁcient ﬂexibility is most important.18 Finally,
when a highly rigid stent is forced to maintain its position at
two locations, there is an increased risk of kinking which
might lead to stenosis (Fig. 4). In the authors’ opinion, an
optimal venous stent should be able to ﬂex at two different
points without narrowing at these ﬂex points (Fig. 4),
thereby preventing kink related stenosis. In general, the
venous anatomy should therefore dictate the shape of the
stent and not vice versa. The sinus Venous stent should
prevent kinking by its segmental design. Connecting rings
with close-cell design creates a high radial force. Connecting
the rings with two tiny connections keeps the system suf-
ﬁciently ﬂexible (Fig. 5). However, a number of concernsn, Germany), versus dedicated venous stent design (sinus Venous
gned stent into a curve increases the risk of kinking. (B) Dedicated
ojection X-ray post stenting with arterial designed stents showing
n the right (black arrow). (D) “S” shape of a venous stent to treat a
Figure 5. 3D CT reconstruction, antero-posterior (A) and oblique (B) after stenting of the left common and external iliac vein clearly
showing the segmented stent design and curved conﬁguration at the level of the internal-external iliac vein conﬂuence and at the level of
the common femoral vein, locations known to be prone to kinking or residual compression.
Initial Sinus-Venous Results 525exist. Most importantly, at the level of the highest external
force the stent segments should be placed in close prox-
imity, to avoid a high pressure point exactly between seg-
ments, which makes delivery technically challenging, with
the most important being the pressure point at the level of
the overriding common iliac artery. A more or less oval
shape can be seen at these levels of high compression, but
a residual stenosis of more than 50% would be unaccept-
able. Other stented segments do not seem to suffer from
focal pressure points. Also, the “bare areas” left between
separate rings do not appear to predispose to restenosis, at
least during the ﬁrst year, as shown in this study.
As shown by Neglén et al., signiﬁcant differences in
outcome can be observed when comparing stenting for
thrombotic and non-thrombotic disease.1 In this series
similar differences were observed; no stents occluded in the
iliac vein compression sub-population, and all three loss of
primary patency instances were seen in the PTS group. The
higher number of re-occlusions in this group might be
caused by the etiology and severity of PTS and compro-
mised venous inﬂow from femoral veins resulting from
extensive post-thrombotic trabeculations. Limitations of
this study include the small population with short median
follow up. Moreover, an in depth comparison with the use
of other stents, especially the Wallstent, has not been
performed.
CONCLUSION
Short-term clinical results using the sinus Venous stent are
excellent, with signiﬁcant symptom reduction, low
morbidity rates, and no mortality. Stent related loss of
patency is seen infrequently. Post-thrombotic lesions
showed a lower patency compared with non-thrombotic
lesions, a known reported ﬁnding.
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